Crucial role of HSP90 in the Akt-dependent promotion of angiogenic-like effect of glucose-regulated protein94 (Grp94)-IgG complexes

Elisa Tramentozzi a, Elena Tibaldi b, Anna Maria Brunati b, Andrea Pagetta a, Paola Finotti a, *

a Department of Pharmacology and Anesthesiology, University of Padova, Largo E. Meneghetti, Padova, Italy
b Department of Biochemistry, University of Padova, Viale G. Colombo, Padova, Italy

Received: October 12, 2010; Accepted: February 8, 2011

Abstract

Previous observations showed that complexes of glucose-regulated protein94 (Grp94) with human IgG, both those isolated from plasma of diabetic subjects and complexes formed in vitro, displayed cytokine-like effects on human umbilical vein endothelial cells (HUVECs), including angiogenic-like transformation capacity that predicted an increased risk of vascular damage. The aim of the present work was to find an effective inhibitor of the angiogenic-like effect of Grp94-IgG complexes. Because this effect is mediated by an increased expression of matrix metalloprotease-9 (MMP-9), we tested the selective MMP-9 inhibitor, the cyclic decapeptide CTT (CTTHWGFTLC) at 5, 10 and 20 μM. CTT failed to inhibit any morphological alteration induced by Grp94-IgG on HUVECs, on its own displaying a paradoxical angiogenic-like activity. We identified the phosphatidylinositol 3-kinase (PI3K)/Akt pathway as the specific target activated by both Grp94-IgG and CTT for sustaining the angiogenic-like transformation of HUVECs. Functioning of the PI3K/Akt pathway was crucially dependent on functional heat-shock protein (HSP)90, and both Grp94-IgG and CTT caused and increased expression of HSP90, promoting its localization to podosomes. CTT appeared to enhance the angiogenic-like effect of Grp94-IgG by increasing the rate of secretion of both HSP90 and MMP-9. By preventing the chaperoning capacity of HSP90 with the inhibitor purine-scaffold (PU)-H71 that blocked the ATP-binding site on HSP90, it was possible to inhibit the expression of Akt and secretion of HSP90 and MMP-9 induced by Grp94-IgG, thus completely reversing the angiogenic pattern. Results reveal a fundamental role of HSP90 in the PI3K/Akt pathway-mediated angiogenic-like effect of Grp94-IgG, also questioning the capacity of CTT to serve as an effective inhibitor of the angiogenic effect.

Keywords: endothelial cells • angiogenic proteins • signal transduction pathways • enzyme inhibitors • heat-shock proteins

Introduction

The role of matrix metalloproteases (MMPs) in remodelling the extracellular matrix and inducing cell migration in both physiological and pathological conditions has been reviewed extensively [1, 2]. In particular, the increased expression and activity of gelatinase MMP-2 and MMP-9 have been demonstrated to contribute to the pathogenesis of several inflammatory diseases and tumours [1, 3–5]. Besides the well-known proteolytic degradation of type IV collagen, MMPs might induce the migration of inflammatory and tumour cells by forming new capillary vessels, concurring in the development of pathological angiogenesis [1, 2, 6]. Of interest is the finding that growth factors and cytokines that stimulate the expression and cellular secretion of heat-shock proteins (HSPs) also stimulate the expression of MMPs, thus enhancing the inflammatory response and promoting its spreading by autocrine–paracrine mechanisms [7–9]. We recently demonstrated that in the plasma of type 1 diabetic subjects the antibody fraction that was stably complexed with the glucose-regulated protein94 (Grp94) stimulated the angiogenic differentiation of human umbilical vein endothelial cells (HUVECs) by a mechanism that involved the increased expression of both HSP90 and HSP70, the latter resulting closely associated with a cell membrane-bound inactive species of MMP-9 [10]. Our results supported the conclusion that circulating Grp94-IgG complexes might be a marker of an increased angiogenic risk sustained by HSP-chaperoned, proteolytically inactive forms of MMP-9. This
Conclusion was in accord with other reports demonstrating that proteolytic activity of MMPs only partially and indirectly is involved in the process of angiogenesis [1]. In order to investigate the molecular mechanism by which Grp94-IgG complexes might act in vivo, we obtained complexes in vitro formed with native Grp94 and human IgG that served as effective substitute of plasma-purified complexes [11]. Effects of Grp94-IgG complexes appeared to be mediated by an increased expression of the MMP-9 pro-form in turn sustained by the activation of the mitogen-activated extracellular kinase1/2 (MEK-ERK1/2) pathway [1, 12]. However, the specific inhibition of the MEK-ERK1/2 pathway failed to affect the MMP-9 expression as well as the angiogenic transformation of HUVECs [11, 12]. With these results in mind, and in light of the implications that inhibition of pathological angiogenesis promoted by a stable rise of angiogenic factors might have for any effective anti-inflammatory and anti-tumour therapy [5, 6], it was of interest to test whether inhibitors of MMPs could antagonize angiogenic-like effect of the Grp94-IgG complexes. Among the several molecules developed as MMP inhibitors, the selective inhibitor of MMP-2 and MMP-9, the cyclic decapeptide CTT (CTTHWGFTLC abbreviated CTT) appeared the best candidate as it was particularly effective in suppressing migration of endothelial cells in vitro, and in preventing tumour growth and invasion in mice [13, 14].

Although the molecular mechanism by which CTT displays its effects is not yet clear [1], it is generally accepted that inhibition of MMP-9 enzyme activity per se is not sufficient to abolish endothelial cell proliferation and migration [1, 14]. It has been proposed that the hydrophobic nature of CTT might favour its binding to phospholipids of the cell membrane, a condition that would permit CTT to target cell surface-bound gelatinases [15].

The aim of our work was thus to test the inhibitory capacity of CTT on angiogenic-like transformation of HUVECs induced by Grp94-IgG complexes formed in vitro. We used these complexes as surrogate of those purified from diabetic plasma, because the latter cannot be obtained in a sufficient amount nor separated in the purification procedures from the bulk of plasma IgG not complexed with Grp94 [10].

Results unexpectedly revealed that CTT not only was completely unable to counteract the effects of Grp94-IgG on HUVECs, but it also displayed similar capacity to stimulate the differentiation process in HUVECs. Inspection of the molecular mechanism involved revealed the importance of HSP90-driven stimulation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in sustaining the angiogenic effect of Grp94-IgG complexes and the role that specific HSP90 inhibitors might thus have in blocking the angiogenic transformation.

Materials and methods

Reagents

Endothelial basal medium (EBM), foetal bovine serum (FBS), antibiotics were from Lonza (Lonza, Walkersville, MD, USA); MMP-2/MMP-9 inhibitor CTT and U0126 were from Calbiochem (Merk KGaA, Darmstadt, Germany); LY294002, human pre-immune IgG, gelatine, endothelial cell growth supplement, bovine serum albumin, MTI (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and Mowiol 40–88 were from Sigma (Sigma Chemicals, St. Louis, MO, USA); anti-human HSP90α/β rabbit polyclonal Abs were from Santa Cruz (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); anti-human rat HSP90α monoclonal, rabbit HSPP70 polyclonal and mouse HSP70 monoclonal Abs were from StressGen (StressGen Biotechnologies, Victoria, B.C., Canada); mouse anti-β actin monoclonal Abs were from Cell Signaling & Neuroscience (Cell Signaling & Neuroscience, St. Louis, MI, USA); anti-MMP-9 mouse monoclonal Abs were from Calbiochem. Anti-Akt and P-Akt Abs were from Santa Cruz Biotechnology Inc. All other reagents were of analytical grade from Sigma.

Grp94-IgG complex

The Grp94-IgG complex was obtained by incubating native Grp94, purified from rat liver microsomal fractions, with human, pre-immune IgG at the molar ratio of 1:1 for 1 hr at 37°C, and its formation tested as previously specified [11]. The Grp94-IgG complex was used in experiments of cell cultures at the final concentration of 10 ng/ml, because in previous experiments this was proven to be effective in supporting the proliferation and angiogenic transformation of HUVECs [11].

Cell cultures

HUVECs were isolated from freshly collected umbilical veins by collagenase treatment [16]. At least three different fresh cords were employed for any cell preparation. Cells were maintained in EBM supplemented with 10% (v/v) FBS, 100 units/ml penicillin, 10 μg/ml streptomycin, 20 μg/ml endothelial cell growth supplement at 37°C in a humidified 95% air, 5% CO2 atmosphere, until the cells reached sub-confluence. Cell culture purity was assessed by microscopic examination of the typical cobblestone morphology and by phycoerythrin (PE) mouse anti-human CD31 monoclonal Abs (BD Pharmingen™, San José, CA, USA). All experiments were performed with HUVECs at passages 3–5.

Cell proliferation assays

Proliferation was evaluated by means of both the MTT test and cell counting. In the former, HUVECs were seeded in the number of 1.5 × 10⁴ in 96-well plates (200 μl well) in EBM supplemented with 10% FBS, under the condition of atmosphere and temperature specified above. After starvation in serum-free medium for 6–8 hrs, cells were supplemented with a fresh aliquot (200 μl) of serum-free medium, without (control) and with Grp94-IgG (10 ng/ml) and CTT, added both singularly and together, in quadruplicate wells. CTT was dissolved in pure de-ionized water with 1% DMSO and used at the final concentrations of 5, 10 and 20 μM C, and its formation tested as previously described with HUVECs [10].
read at 570 and 630 nm and the difference between the two wavelengths taken as the value expressing the proliferation value.

In other experiments, HUVECs (25 × 10^4/well) were seeded in 12-well (2 ml each) plates and allowed to attach to well plastics for 24 hrs. Cells were then starved in fresh, serum-free medium for 6–8 hrs and after this time, aliquots of both Grp94-IgG complex and CTT solutions added in fresh medium, as specified above for the MTT assay. After incubation at 18 hrs, the medium was collected and stored at –20°C before further analysis, cells washed with PBS, detached from duplicate wells by adding 0.05% trypsin and 0.2% ethylenediamine tetraacetic acid (EDTA), and counted in a haemocytometer. Cell viability was evaluated with the trypan blue dye exclusion method.

In experiments in which inhibitors were tested, these were added to the cell culture 15 min. before the addition of Grp94-IgG complex solution (where specified). The MEK-ERK1/2 inhibitor U0126 was employed at the final concentration of 10 μM, whereas the PI3K/Akt pathway inhibitor LY294002 was used at final concentrations of 25, 20, 15, 10 and 5 μM.

Analysis of cell lysates

After each incubation time, cells were washed with PBS, scraped and centrifuged for 15 min. at 600 × g. After removal of the supernatant, cells were lysed in the Laemmli lysis buffer (50 mM Tris-HCl, pH 8.8, 5 mM EDTA, 380 mM glycine, 2% SDS) (whole lysates). Proteins were measured by the micro-BCA assay (Pierce, Rockford, IL, USA), unless otherwise specified. Whole lysates were then analysed by SDS-PAGE on 10% polyacrylamide gel, followed by blotting on a nitrocellulose membrane for measuring ERK1/2 and Akt activity with total and phospho(P)-specific ERK1/2 polyclonal Abs (Cell Signaling & Neuroscience) and with total and P-Akt-specific polyclonal Abs. Immuno-detection was performed with either the enhanced luminal-based chemiluminescent system (Amersham Biosciences, Uppsala, Sweden) or phosphatase alkaline-conjugate, affinity-purified IgG (from Sigma) and biotin conjugate, affinity-purified IgG (Vector Laboratories, Burlingame, CA, USA) coupled with white avidin conjugated to alkaline phosphatase (ABC system). Abs against β actin were used as controls for protein loading.

In separate experiments, cell lysis was also performed in sterile de-ionized water followed by centrifugation at 100,000 × g for 90 min. The supernatant was collected (cytosol fraction) and the pellet (membrane fraction) treated with the Laemmli buffer (native lysates). The pellets were then analysed by SDS-PAGE on 4–20% gradient polyacrylamide gel followed by immunoblotting with anti-HSP70, anti-HSP90/α and anti-MMP-9 Abs.

Analysis of media

Media from duplicate wells of control and treated HUVECs were collected, centrifuged for 10 min. at 800 × g to remove cell debris, and dialysed overnight at 4°C against high grade pure distilled water. The lyophilized material was re-suspended in 100 μl of sample buffer (0.125 M Tris-HCl, pH 6.8, 20% glycerol, 4% SDS) before submitting samples to SDS-PAGE (10% polyacrylamide gel) and Western blotting with anti-MMP-9, anti-HSP90/α and HSP70 Abs. Proteolytic activity of media was measured by means of zymogram gel analysis by loading samples on to the polyacrylamide gel (10%) co-polymerized with gelatin (0.8 mg/ml) in the presence of SDS. After repeated washings (15 min. each) with the renaturing solution (2.5% Triton X-100), the gel was incubated overnight at 37°C in a solution of Tris buffer (50 mM Tris-HCl and 10 mM CaCl2, pH 7.4) under slow shaking. The gel was then submitted to staining with Coomassie brilliant blue, followed by de-staining with a 5% methanol and 7.5% acetic acid solution (in de-ionized water) until clear bands appeared against the blue background.

Immunofluorescence microscopic analysis

Cells (15 × 10^4/well) were seeded in 24-well (1 ml each) plates with detachable glass bottom. After an 8-h starvation, a serum-free aliquot of fresh medium was added without (control) and with Grp94-IgG complexes (10 ng/ml) and 10 μM CTT, added both singularly and together. CTT was added to the cell culture 15 min. before the addition of the Grp94-IgG complex solution. After 16 hrs incubation, glass bottom of each well was gently detached and cells fixed with 4% formaldehyde in PBS for 15 min., washed three times, and treated with 0.1% Triton X-100 in PBS at room temperature for 10 min. After two further washings with PBS, cells were incubated for 30 min. with blocking buffer (PBS containing 1% bovine serum albumin), washed twice with PBS and incubated for 2 hrs at 37°C with both phallolidin (Molecular Probes, Invitrogen Corp., Carlsbad, CA, USA) in PBS (at a 1:100, v:v ratio), to evaluate overall cell morphology and the actin cytoskeleton, and rabbit anti-human HSP90/α and HSP70 Abs (1:100, v:v ratio). Alexa Fluor 488 goat anti-rabbit IgG (1:350, v:v ratio, Molecular Probes) were then added to detect the fluorescent signal of both HSP90 and HSP70. After incubation with specific Abs for 1 hr at room temperature, cells were treated with 21 μg/ml DNase-free RNase in PBS for 10 min. at room temperature. Then, cells were treated with red fluorescent Propidium iodide for nuclear and chromosome counterstaining (Molecular Probes), added to Mowiol 40–88 at the final concentration of 0.5 μg/ml.

Statistical analysis

Data were presented as mean ± S.D. unless otherwise stated. GraphPad Prism (GraphPad software, Inc. San Diego, CA, USA) was used for the statistical analysis of data. Comparison between group means was made by applying the two-tailed, unpaired Student’s t-test. A P-value <0.05 was considered statistically significant.

Results

CTT inhibits cell growth stimulation but not angiogenic-like transformation of HUVECs induced by Grp94-IgG

We used CTT at concentrations of 5, 10 and 20 μM which comprised the IC50 of gelatinase activity in vitro (5 μM) and the concentration at which CTT is reported to partially inhibit human endothelial cell migration (20 μM) [13]. We considered these concentrations more physiological than the higher ones (up to 500 μM) used to obtain more effective inhibitory activity by CTT [13] but driving the risk of unspecific effects in experiments in vitro.

Grp94-IgG complex (10 ng/ml) stimulated the cell growth by 20% ± 5.44 (mean ± S.E.M., n = 11) a value statistically significant with respect to the control (P = 0.02, two-tailed Student’s
This effect was abolished by CTT at 5 and even more at 10 μM (mean ± S.E.M. cell growth reduction with respect to the control: 22% ± 6.63, n = 11, P = 0.039, two-tailed Student’s t-test). CTT on its own did not affect at all the proliferation of HUVECs at any of the concentrations used (Fig. 1A).

Microscopic inspection of cell morphology besides confirming the angiogenic-like transformation of HUVECs by Grp94-IgG, unexpectedly showed that CTT was not only unable to antagonize the angiogenic-like transformation of HUVECs by Grp94-IgG but also on its own displayed changes in morphology of HUVECs that mostly at 20 μM overlapped those induced by Grp94-IgG alone (Fig. 1B). Apparently, thus, while inhibiting the proliferative effect of Grp94-IgG on HUVECs, CTT left unaltered the angiogenic-like transformation, a result that suggested a distinct mechanism of action in the activation of either one process by Grp94-IgG.

Fig. 1 Effects of CTT on cell growth and morphology of HUVECs in absence and presence of Grp94-IgG complexes. (A) Cells were seeded (1.5 × 10⁴) and cultured as specified in ‘Materials and methods’ in absence (control) and presence of Grp94-IgG complexes (10 ng/ml) added both alone and with CTT at the indicated concentrations. After 18 hrs incubation, cells were treated with MTT (see ‘Materials and methods’) and the entity of proliferation (on the ordinate axis) expressed as the difference of the absorbance values measured at 570 and 630 nm. (B) Cells (25 × 10⁴) were cultured in duplicate wells (2 ml) with both CTT and Grp94-IgG complexes, as above, and after 18 hrs incubation, analysed at the optical microscope. Representative pictures of each condition are shown with original magnification of 10×.

The MEK-ERK1/2 pathway is dispensable for the angiogenic-like effect of the Grp94-IgG complex

We previously demonstrated that both the stimulation of endothelial cell proliferation and induction of differentiation by Grp94-IgG were
mediated by an intense activation of the MEK-ERK1/2 pathway, even higher than that observed with native Grp94 alone [11]. An intense and prolonged activation of ERK1/2 is recognized to underlie the differentiation of HUVECs into tubule-like formations [17, 18]. Because CTT on its own was apparently as active as Grp94-IgG in inducing the differentiation process of endothelial cells, it was of interest to see whether MEK-ERK1/2 pathway was further stimulated by the addition of CTT. After 18 hrs incubation, an intense phosphorylation of ERK1/2 was observed with Grp94-IgG (Fig. 2A), further stimulated by pre-treatment with CTT, irrespective of the concentration, a finding that supported the permissive effect of CTT on the induction of angiogenic-like transformation of HUVECs. The same result however excluded that the MEK-ERK1/2 pathway was directly involved in mediating the inhibition of cell proliferation by CTT, because CTT alone did not affect at all the phosphorylation of ERK1/2 (the signal was even lower than that of control) (Fig. 2A), the effect of enhancement of ERK1/2 phosphorylation by CTT could be explained by invoking an indirect mechanism of activation by CTT on a pathway, also targeted by Grp94-IgG, other than the MEK-ERK1/2 one.

That the differentiation effect of Grp94-IgG on HUVECs was independent of the MEK/ERK1/2 pathway was confirmed by experiments in which cells were treated with the MEK/ERK1/2 inhibitor U0126 (10 μM, final concentration) before the addition of both Grp94-IgG and CTT. Although U0126 markedly reduced the ERK1/2 phosphorylation in both control and Grp94-IgG-treated cells, with or without CTT, it nevertheless left unchanged the effect of Grp94-IgG on cell differentiation, both in absence and presence of CTT, (data not shown), i.e. cell morphology was similar to that observed in absence of U0126. This finding further corroborated the idea that Grp94-IgG sustains the angiogenic-like transformation of HUVECs mainly targeting cellular pathways other than the MEK-ERK1/2 that might be involved secondarily through the cross-talk with closely associated pathways(s) eventually leading to the intense downstream activation of P-ERK1/2 [11].

The PI3K/Akt pathway mediates the angiogenic-like effect of the Grp94-IgG complex

The possibility was then considered that the PI3K/Akt pathway could mediate effects of Grp94-IgG on HUVECs, because this pathway plays a pivotal role in the process of endothelial cell proliferation and differentiation [19]. Both total and phosphorylated forms of Akt of cell lysates were intensely stimulated by Grp94-IgG after 18 hrs incubation (Fig. 2B), a finding that closely resembles what has been observed with some angiogenic promoters (such as VEGF) that affect the Akt activity not only at the level of phosphorylation but also modifying the expression of the protein by a receptor-mediated mechanism of activation of regulatory cellular pathways [20]. CTT was able to antagonize the stimulatory effect of Grp94-IgG at both 10 and 20 μM but not at 5 μM, although inhibition did not restore values of Akt and P-Akt to values of the control (Fig. 2B). At variance with what observed on the ERK1/2 phosphorylation, CTT on its own stimulated the PI3K/Akt pathway by increasing the expression of both Akt and P-Akt, although the overall effect was at any concentration of CTT less intense than that of Grp94-IgG alone. Thus, despite the independent activation of the PI3K/Akt pathway by Grp94-IgG and CTT, the association led to a reduction of the stimulatory effect of Grp94-IgG by CTT, in a concentration-dependent manner.

HSP90 is involved in the activation of the PI3K/Akt pathway by both Grp94-IgG and CTT

It has been reported that intracellular Akt is a client protein of HSP90 that forms complexes in which Akt is stabilized and rendered functionally active [21]. Results of our previous work supported the proposal that the angiogenic effect of Grp94-IgG is
mediated by autocrine–paracrine mechanisms of activation of HSP90 and HSP70 [11]. Thus, if CTT was able to inhibit the Grp94-IgG dependent activation of the PI3K/Akt pathway by positively targeting the same pathway, one might expect that the HSP90 expression were similarly affected. To investigate this issue, we performed immunofluorescence experiments with both anti-HSP90 and anti-HSP70 Abs on HUVECs treated with Grp94-IgG and CTT at 10 μM, both alone and together. In the former experiment, Grp94-IgG induced the appearance of numerous podosomes in HUVECs in which the HSP90-related fluorescence concentrated mostly in association with actin (Fig. 3, panels b), to testify the intense cytoskeleton modification accompanying proliferation and angiogenic transformation of cells. CTT at 10 μM led to a significant reduction in both the podosomes number and HSP90-dependent fluorescence sustained by Grp94-IgG, although it did not antagonize completely this effect, and HSP90 expression appeared to be still increased with respect to the control (Fig. 3, panels d). CTT alone was as effective as Grp94-IgG in stimulating the podosome formation and in inducing the expression of HSP90 (Fig. 3, panels c), a result that fit both the morphological alteration and stimulation of Akt observed with CTT alone. The results also pointed to the close molecular link between activation of the Akt pathway and increased expression of HSP90 in the cell membrane, as predicted by the function of HSP90 in remodelling the actin cytoskeleton during cell differentiation and migration [22].

At variance with HSP90, the expression of HSP70 in immunofluorescence experiments, although increased with respect to the control after treatment with Grp94-IgG, was neither so intense, nor was it modified at all by CTT (data not shown). Because CTT per se did not affect the expression of HSP70 (data not shown), the results supported the possibility that induction of the HSP70 expression during HUVEC differentiation is under the control of pathways, targeted by Grp94-IgG but not by CTT, distinct from the PI3K/Akt.

To confirm results of experiments of immunofluorescence, we also conducted immunoblotting experiments on lysates of HUVECs obtained in native conditions, in which the membrane fraction was separated from cytosol and the expression of HSP90 measured on the pellet for the most part formed with cell membrane. HSP90 was almost absent in cell membranes of control
HUVECs, whereas it was markedly increased with both Grp94-IgG and CTT alone (Fig. 4A). When added together, CTT inhibited the stimulation of HSP90 by Grp94-IgG at 10 \( \mu \)M but not at 5 \( \mu \)M, thus confirming the antagonism seen in immunofluorescence experiments.

Because membrane-bound HSP90, i.e. HSP90 associated with cytoskeleton proteins, such as actin, does not give a true information about the whole cell expression of HSP90, mostly confined to the cytoplasm, nor is it an index of the extent of HSP90 secretion, we performed experiments of immunoblotting on whole cell lysates and in media of cells treated with Grp94-IgG in both absence and presence of 10 \( \mu \)M CTT. It was thus apparent that CTT was as able as Grp94-IgG in stimulating the expression of HSP90 in HUVECs, but it was ineffective in reducing the stimulation sustained by Grp94-IgG (Fig. 4B), a finding that was at odds with results of immunofluorescence experiments. Similarly, measurements of HSP90 in media showed that CTT, instead of inhibiting, further increased the stimulation of HSP90 secretion by Grp94-IgG (Fig. 4C). Thus, not only was the expression of HSP90 in HUVECs left unchanged, or even increased by CTT in both absence and presence of Grp94-IgG, but also the antagonism exerted by CTT on the Grp94-IgG dependent stimulation of HSP90 in the cell membrane was only apparent, reflecting instead the capacity of CTT to enhance the effect of Grp94-IgG to stimulate the rate of HSP90 secretion.

**CTT does not counteract the effects of Grp94-IgG on the MMP-9 expression and secretion**

It has firmly been established that mitogenic stimuli that promote cell proliferation and differentiation also lead to an increased expression of MMP-9 [23], and that MMP-9 expressed by endothelial cells is critical for inducing angiogenesis [6, 12]. However, mechanisms by which MMP-9 might contribute to the development and progression of angiogenesis are still controversial, although it appears to be for most part independent of MMP-9 proteolytic activity [10, 11, 24]. Despite the intensive effort spent in this direction, the signal transduction pathway(s) specifically involved in regulating the expression of MMP-9 following application of various stimuli has not been identified with precision. While the phosphorylation of ERK1/2 appears to be not sufficient for the expression of MMP-9 [12], the role of activated PI3K/Akt pathway in driving stimulation of MMP-9 production and secretion [8, 25] has been considered with much higher relevance. In immunoblotting experiments with monoclonal anti-MMP-9 Abs
by an HSP90-dependent activation of the Akt pathway, we searched whether an inhibitor of this pathway could effectively antagonize the major Grp94-IgG effect on HUVECs. To this aim, we chosen an inhibitor of the HSP90 function that causes down-regulation of the Akt kinase-dependent pathway instead of the classic inhibitor LY294002 that in our cell cultures reduced cell viability by 40% in control HUVECs even at concentrations as low as 5 μM (data not shown). We thus employed the novel pan-HSP90 inhibitor, the non-quinone PU-H71, already successfully used in cancer cell cultures and in vivo to reduce up-regulation of HSP90 and to inhibit the expression of Akt in a dose-dependent manner [26, 27]. PU-H71 was added to cell cultures 15 min. before the addition of Grp94-IgG at the final concentrations of both 50 nM (IC50) and 150 nM, to measure to what extent effects of Grp94-IgG were dependent on the PI3K/Akt pathway activation. Stimulation of HSP90 expression by Grp94-IgG was inhibited by PU-H71 in a dose-dependent manner, as demonstrated by immunoblotting on whole cell lysates (Fig. 6A). A much higher, dose-dependent inhibitory effect was observed with PU-H71 on the HSP90 secretion in culture media where HSP90 was barely detectable already at 50 nM PU-H71 (Fig. 6B). It is worth noting that the same effect was also present with PU-H71 alone, as if the inhibition of HSP90 as such could lead to the block of HSP90 secretion.

PU-H71 at its lower concentration did not reduce significantly the Akt expression in cell lysates treated with Grp94-IgG (data not shown), whereas markedly inhibited Akt and P-Akt at 150 nM (Fig. 7). No substantial modification in the Akt activity was instead noted with PU-H71 alone. Results suggest that PU-H71 can antagonize the effects induced by Grp94-IgG on cellular HSP90, mostly affecting the delivery to cell membrane and secretion of HSP90 from the cell. This would imply interference with mechanisms of autocrine–paracrine activation of cell proliferation and angiogenic differentiation promoted by HSP90.

**PU-H71 inhibits the MMP-9 pro-form expression and the angiogenic-like transformation of HUVECs induced by Grp94-IgG**

The effective inhibition by PU-H71 of the HSP90 expression and secretion stimulated by Grp94-IgG would predict antagonism on the angiogenic-like promoting activity of Grp94-IgG. In addition, because MMP-9 is actively involved in the angiogenic process, and its stimulation by Grp94-IgG is mediated by HSP90-dependent Akt activation, it would be expected that the expression of MMP-9 were similarly inhibited by PU-H71. Experiments of zymography showed that PU-H71 at the highest concentration caused a significant reduction in the secretion of MMP-9 pro-form stimulated by Grp94-IgG (Fig. 8). This result indirectly proved that the Akt pathway was involved in the process of MMP-9 transport to the membrane and secretion from the cell that is functional to the diffusion of angiogenesis.

Optical microscopy inspection also revealed that PU-H71 was able to restore, in a concentration-dependent manner, the normal morphology of HUVECs, the tubule-like formations induced by Grp94-IgG being completely antagonized at 150 nM PU-H71 (Fig. 9).
Discussion

In this work we tested the selective MMP-2 and MMP-9 inhibitor, the cyclic decapeptide CTT as a potential inhibitor of proliferation and angiogenic-like transformation of HUVECs induced by complexes of Grp94-IgG. The choice of CTT was dictated by the previous observations showing that effects of complexes Grp94-IgG on...
HUVECs were mediated by an increase in the expression and activity of MMP-9 [11], and MMPs are known to play a crucial role in sustaining angiogenesis and endothelial cell migration in pathological conditions [2, 6]. Grp94-IgG complexes isolated from the plasma of diabetic subjects were identified as a marker of increased risk for developing vascular alterations that in time lead to stable and severe complications characterizing diabetes [10]. Thus, because CTT was proven effective in blocking angiogenesis and invasion of the blood vessel wall in tumour cells, thanks to specific anti-gelatinase activity [6, 13], morphological alterations induced by Grp94-IgG on endothelial cells might also be expected to be inhibited by CTT, thus supporting the use of CTT as anti-angiogenic agent also in conditions characterized by an increased concentration of these circulating complexes [10].

Results allowed us to address in depth the still unmet question of the molecular pathway specifically targeted by Grp94-IgG complexes for inducing morphological alterations in endothelial cells [11]. At the same time, we faced unexpected paradoxical biological effects of CTT. In particular, not only was CTT unable to inhibit angiogenic-like effects on HUVECs, but it even displayed a dose dependent, pronounced capacity to induce angiogenic transformation of cells (Fig. 1). This effect, apparently negating any anti-angiogenic activity, might be explained by considering that CTT is able to bind to structures on the cell membrane that activate mechanisms of intracellular signal transduction, similar to those involved by Grp94-IgG complexes. Although CTT homing to the vasculature in tumours has been explained by its binding to MMP-9 over-expressed on endothelial cells of newly formed vessels [13], hydrophobic nature of CTT, including its crucial HWGF sequence [13], can per se justify binding at sites in the membrane other than the specific membrane-bound target of MMP-9, as also supported by experiments demonstrating incorporation of CTT into phospholipids in liposomes [15]. Although to our knowledge no other MMP inhibitor has been observed to have a clear-cut angiogenic activity on HUVECs as CTT did, it is worth mentioning that a paradoxical cell growth stimulating and pro-angiogenic property is reported to occur also with tissue inhibitors of metalloproteases and other synthetic MMP inhibitors on certain cancer cell lines [28]. Importantly also, these unexpected, unwanted effects appeared to be independent of the MMP-inhibitory activity [1, 28], being instead mediated by specific structures on the cell membrane [28]. Inspection of the molecular mechanisms underlying the apparent synergistic effect of CTT on angiogenic transformation by Grp94-IgG, excluded that the MEK-ERK1/2 pathway played a major role. This conclusion was supported by the following observations. First, CTT per se did not affect this pathway, although it turned out to enhance the intense ERK1/2 phosphorylation promoted by Grp94-IgG (Fig. 2), a result that confirmed the capacity of Grp94-IgG to directly stimulate the MEK/ERK1/2 pathway [11]. In addition, the specific MEK-ERK1/2 inhibitor U0126, while reducing the degree of ERK1/2 phosphorylation, did not change at all the morphological alterations induced by Grp94-IgG and CTT, both alone and together (data not shown). It was thus apparent that the differentiation effect of Grp94-IgG on HUVECs was mediated by another signalling transduction pathway also targeted by CTT, and that CTT was able to enhance the ERK1/2 phosphorylation driven by Grp94-IgG by activating this pathway (Fig. 2).

We present experimental evidence showing that the PI3K/Akt pathway is targeted by both Grp94-IgG and CTT, and that angiogenic-like effects on HUVECs are promoted by an HSP90-dependent activation of this pathway. Both Grp94-IgG and CTT were able to increase cellular expression of Akt and P-Akt, although Grp94-IgG was much more effective than CTT in this respect (Fig. 2). Intriguingly, however, when added together, the stimulation due to Grp94-IgG was reduced, although the expression of Akt remained still higher than the control. This result did not fit the picture of morphological alterations that even worsened when CTT was added to Grp94-IgG (Fig. 1). Because Akt pathway plays a pivotal role in mediating angiogenic effects [19, 25], a reduction of Akt expression would be expected to lead to a parallel reduction in morphological alteration. To search for a mechanism accounting for this contradictory result, we focused the attention on HSP90, because HSP90 is actively involved in mediating effects of Grp94-IgG on HUVECs [11]. HSP90 is the
Grp94-IgG is entirely sustained by an HSP90-dependent activation destabilized [21]. Therefore, the inhibitory effect of CTT on Akt expression stimulated by Grp94-IgG might also be explained by reduction in either the expression or availability of HSP90. Experiments of immunofluorescence and immunoblotting on cell lysates—both whole and native lysates—clearly demonstrated that cell expression of HSP90 was slightly increased, not reduced, under the stimuli of Grp94-IgG and CTT, both alone and together (Fig. 4). However, whereas in the presence of both Grp94-IgG and CTT alone, HSP90 was almost entirely confined to cell membrane in podosomes (Fig. 3), the association led to a marked decrease in membrane-bound HSP90 (Figs 3 and 4). Thus, both Grp94-IgG and CTT might promote angiogenic transformation of HUVECs by stimulating the expression of HSP90 that was confined to the membrane in podosomes, where it is present in complexes with structural proteins—that account for intense structural modifications of actin cytoskeleton during differentiation of endothelial cells [31, 32]—and with proteins destined to secretion, such as MMPs [1, 10]. Several reports document that both active and inactive forms of MMP-9 are present in podosomes following the application of mitogenic stimuli [8, 34–36], and shedding of MMP-9 is responsible for the proteolytic activity functional to paracrine diffusion of morphogenetic alterations during angiogenesis [8, 34].

Although we were unable to measure MMP-9 expression in cell lysates—MMP-9 is hardly detected as protein in HUVECs [12]—the experiments of gel zimography clearly demonstrated that MMP-9 is intensely secreted in its inactive form in the presence of Grp94-IgG and CTT, and that association further increased the MMP-9 secretion (Fig. 5). This finding, together with the observation that also HSP90 underwent similar intense secretion, mostly when CTT was added to Grp94-IgG (Fig. 4), support the proposal that CTT enhances the angiogenic effect of Grp94-IgG by promoting the secretion of complexes of HSP90 with MMP-9, both concurring in reinforcing and propagating the mechanisms of angiogenic transformation and cell migration. Thus, reduction of both cellular Akt and membrane-bound HSP90 observed when CTT is added to Grp94-IgG does not mean that effects of Grp94-IgG are antagonized and that CTT might be taken as an effective inhibitor of Grp94-IgG on HUVECs. Results of immunofluorescence experiments rather indicate that CTT in the presence of Grp94-IgG alters the intra-cellular availability of HSP90, by accelerating its secretion. Although we did not investigate in details specific molecular aspect, it is tempting to speculate that an increased demand of HSP90 for chaperoning cellular MMP-9 that is stimulated by both Grp94-IgG and CTT (Fig. 5) might partially and temporarily divert HSP90 from forming complexes with Akt that might thus be destabilized [21].

We offered a further proof that the angiogenic-like effect of Grp94-IgG is entirely sustained by an HSP90-dependent activation of the PI3K/Akt pathway, by using an HSP90 inhibitor, the non-quinone PU-H71 that down-regulates the PI3K/Akt pathway. PU-H71 does not affect cell viability, at variance with the classic PI3 kinase inhibitor LY294002 that in our cell culture drastically reduced cell viability even at the lowest concentration of 5 μM (data not shown). By occupying the ATP-binding site in HSP90, PU-H71 induces structural conformation in HSP90 that prevents binding of client proteins and their proper folding and activation [37, 38]. This mechanism is exploited for blocking over-expression of oncoproteins in cancer cells that require HSP90 for establishing their malignant phenotype, and purine-scaffold inhibitors of HSP90 are emerging as promising anti-tumour agents in clinical practice [39]. We observed that PU-H71 reduced in a concentration-dependent manner the stimulation of cellular HSP90 and Akt by Grp94-IgG, and in addition caused a marked fall in the secretion of HSP90 (Figs 6 and 7). This last effect was also displayed by PU-H71 alone, a result that suggested a mechanism by which the structural modification that HSP90 undergoes following inhibition prevents it from reaching the membrane and being secreted. This mechanism should also be supported by the observation that, in parallel with inhibition of HSP90 secretion, PU-H71 caused a fall in the MMP-9 secretion (Fig. 8), thus confirming that HSP90 is the chaperone of MMP-9 and that complexes of HSP90 with MMP-9 are delivered to the membrane and secreted during angiogenesis. In accord with the proposal that secretion of HSP90 and MMP-9 should be relevant for the induction of angiogenesis, and that blocking this secretion should also inhibit angiogenesis, we demonstrated that PU-H71 was able to reverse in a concentration-dependent manner the angiogenic transformation induced by Grp94-IgG, restoring completely the normal morphology in HUVECs (Fig. 9).

One would argue that effects observed with PU-H71 might be partly (if not entirely) due to inhibition of the ATP binding site on Grp94 rather than (or in addition to that) on HSP90, considering that PU-H71 is a pan-HSP90 inhibitor. However, different observations rule out this possibility. First, the availability of ATP binding site on Grp94 is strongly limited, if not precluded by steric constraint of Grp94 in the complex [11]. Indeed, at variance with what occurs with free Grp94, the addition of ATP to the complex does not modify the Grp94 conformation at all (personal observation). Second, PU-H71 is added to cell cultures 15 min. before the addition of Grp94-IgG, a procedure that permits the inhibitor to enter the cells and bind to HSP90, as demonstrated by the inhibition of HSP90 secretion by PU-H71 in absence of Grp94-IgG (Fig. 8). Finally, both the steric hindrance of the complex and the fact that its effects on HUVECs are mediated by a cell-surface receptor activation [11] favour the extracellular localization of Grp94-IgG rather than its internalization, being thus Grp94 also spatially prevented from taking contact with the inhibitor.

In conclusion, our work has revealed the essential role of HSP90 in the activation of the PI3K/Akt pathway that is targeted by Grp94-IgG for displaying the angiogenic-like effect on HUVECs. HSP90 appears as a promising therapeutic target for antagonizing the Akt-mediated mechanisms of activation of angiogenesis.
because it also supports the activation and secretion of MMP-9. Incidentally, we discovered paradoxical effects of the MMP-9 inhibitor CTT that on its own exhibited angiogenic-like property. This raises doubts about the claimed role of CTT as inhibitor of angiogenesis in pathological conditions [40]. Although the mechanisms underlying these effects of CTT on HUVECs deserve further investigation, our present results may nevertheless offer a molecular basis for explaining the disappointing effects observed with MMP inhibitors [2, 5, 28, 41] and that drastically hampered the use of MMP inhibitors, including CTT, as effective anti-angiogenic and anti-tumour agents [41].

References

1. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005; 1755: 37–69.
2. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999; 103: 1237–41.
3. MacFadyen RJ. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine? Curr Opin Pharmacol. 2007; 7: 171–8.
4. Jacqueminet S, Ben Abdesselam O, Chapman MJ, et al. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta. 2006; 367: 103–7.
5. Hu J, Van den Steen PE, Sang QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007; 6: 480–98.
6. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2: 737–44.
7. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem. 1993; 53: 288–95.
8. Redondo-Munoz J, Escobar-Diaz E, Samaniego R, et al. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by α4β7 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood. 2006; 108: 3143–51.
9. Di Girolamo N, Indoh I, Jackson N, et al. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J Immunol. 2006; 177: 2638–50.
10. Tramentozzi E, Pagetta A, Frasson M, et al. Angiogenic transforming capacity of IgG purified from plasma of type 1 diabetic patients. J Cell Mol Med. 2009; 13: 1336–47.
11. Tramentozzi E, Montopoli M, Orso G, et al. Stable complexes formed by Grp94 with human IgG promoting angiogenic differentiation of HUVECs by a cytokine-like mechanism. Mol Immunol. 2008; 45: 3639–48.
12. Genersch E, Hayess K, Neuenfeld Y, et al. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J Cell Sci. 2000; 113: 4319–30.
13. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999; 17: 768–74.
14. Bjorklund M, Heikkila P, Koivunen E. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J Biol Chem. 2004; 279: 29859–97.
15. Medina OP, Soderlund T, Laakkonen LJ, et al. Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 2001; 61: 3978–85.
16. Jaffe EA, Nachman RL, Becker CG, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973; 52: 2745–56.
17. Ebisuya M, Kondo K, Nishida E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. J Cell Sci. 2005; 118: 2997–3002.
18. Murphy LS, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci. 2006; 31: 268–75.
19. Somanath PR, Razorenova OV, Chen J, et al. Akt1 in endothelial cell and angiogenesis. Cell Cycle. 2006; 5: 512–8.
20. Fieber CB, Eldridge J, Taha TA, et al. Modulation of total Akt kinase by increased expression of a single isoform: requirement of the sphingosine-1-phosphate receptor, Edg3/S1P3, for the VEGF-dependent expression of Akt3 in primary endothelial cells. Exp Cell Res. 2006; 312: 1164–73.
21. Basso AD, Solit DB, Chiosis G, et al. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem. 2002; 277: 39856–66.
22. Liang P, MacRae TH. Molecular chaperones and the cytokines. J Cell Sci. 1997; 110: 1431–40.
23. Melamed D, Messika O, Glass-Marmor L, et al. Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoesis. Int Immunol. 2006; 18: 1355–62.
24. Mason DP, Kenagy RD, Hasenstab D, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res. 1999; 85: 1179–85.
25. Ruhul Amin AR, Senga T, Do ML, et al. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1β: a role for the dual signalling pathways, Akt and Erk. Genes Cells. 2003; 8: 515–23.
26. Breinig M, Caldas-Lopes E, Goeppert B, et al. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology. 2009; 50: 102–12.

Conflict of interest

The authors confirm that there are no conflicts of interest.

Acknowledgements

We thank Dr. Gabriela Chiosis of Memorial Sloan-Kettering Cancer Center (New York, NY) for the generous gift of the HSP90 inhibitor PU-H71. The paper was supported by MIUR (Ministero dell’Istruzione, dell’Università e della Ricerca) grants ex-60%.

J. Cell. Mol. Med. Vol 15, No 12, 2011

© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd

2779
27. Luo W, Dou F, Rodina A, et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. *Proc Natl Acad Sci USA*. 2007; 104: 9511–6.

28. Porter JF, Shen S, Denhardt DT. Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. *Br J Cancer*. 2004; 90: 463–70.

29. Shinozaki F, Minami M, Chiba T, et al. Depletion of hsp90beta induces multiple defects in B cell receptor signaling. *J Cell Physiol*. 1998; 176: 150–65.

30. Aligue R, Akhavan-Niak H, Russell P. A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. *EMBO J*. 1994; 13: 6099–106.

31. Pawlowska Z, Baranka P, Jerczynska H, et al. Heat shock proteins and other components of cellular machinery for protein synthesis are up-regulated in vascular endothelial cell growth factor-activated human endothelial cells. *Proteomics*. 2005; 5: 1217–27.

32. Wojciak-Stothard B, Entwistle A, Garg R, et al. Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. *J Cell Physiol*. 1998; 176: 150–65.

33. Citri A, Harari D, Shohat G, et al. Hsp90 recognizes a common surface on client kinases. *J Biol Chem*. 2006; 281: 14361–9.

34. Taraboletti G, D’Ascenzo S, Borsotti P, et al. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. *Am J Pathol*. 2002; 160: 673–80.

35. Nguyen M, Arkell J, Jackson CJ. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. *J Biol Chem*. 1998; 273: 5400–4.

36. Toth M, Gervasi DC, Fridman R. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. *Cancer Res*. 1997; 57: 3159–67.

37. Shiu AK, Harris SF, Southworth DR, et al. Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. *Cell*. 2006; 127: 329–40.

38. Pratt WB, Morishima Y, Osawa Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. *J Biol Chem*. 2006; 283: 22885–9.

39. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multi-modal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. *Proc Natl Acad Sci USA*. 2009; 106: 8368–73.

40. Folkman J. Angiogenic zip code. *Nat Biotechnol*. 1999; 17: 749.

41. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. *Science*. 2002; 295: 2387–92.